From tau phosphorylation to tau aggregation: what about neuronal death?

Tau pathology is characterized by intracellular aggregates of abnormally and hyperphosphorylated tau proteins. It is encountered in many neurodegenerative disorders, but also in aging. These neurodegenerative disorders are referred to as tauopathies. Comparative biochemistry of the tau aggregates shows that they differ in both tau isoform phosphorylation and content, which enables a molecular classification of tauopathies. In conditions of dementia, NFD (neurofibrillary degeneration) severity is correlated to cognitive impairment and is often considered as neuronal death. Using tau animal models, analysis of the kinetics of tau phosphorylation, aggregation and neuronal death in parallel to electrophysiological and behavioural parameters indicates a disconnection between cognition deficits and neuronal cell death. Tau phosphorylation and aggregation are early events followed by cognitive impairment. Neuronal death is not observed before the oldest ages. A sequence of events may be the formation of toxic phosphorylated tau species, their aggregation, the formation of neurofibrillary tangles (from pre-tangles to ghost tangles) and finally neuronal cell death. This sequence will last from 15 to 25 years and one can ask whether the aggregation of toxic phosphorylated tau species is a protection against cell death. Apoptosis takes 24 h, but NFD lasts for 24 years to finally kill the neuron or rather to protect it for more than 20 years. Altogether, these data suggest that NFD is a transient state before neuronal death and that therapeutic interventions are possible at that stage.

[1]  P. Hof,et al.  Cell-Cycle Reentry and Cell Death in Transgenic Mice Expressing Nonmutant Human Tau Isoforms , 2005, The Journal of Neuroscience.

[2]  P. Hof,et al.  Pathological τ proteins in postencephalitic parkinsonism: Comparison with Alzheimer's disease and other neurodegenerative disorders , 1997 .

[3]  M. Garcia-Blanco,et al.  Correction of tau mis-splicing caused by FTDP-17 MAPT mutations by spliceosome-mediated RNA trans-splicing , 2009, Human molecular genetics.

[4]  D. Campion,et al.  Inhibition of proteasome and Shaggy/Glycogen synthase kinase‐3β kinase prevents clearance of phosphorylated tau in Drosophila , 2006, Journal of neuroscience research.

[5]  L. Buée,et al.  Neurogenesis and cell cycle-reactivated neuronal death during pathogenic tau aggregation , 2007, Genes, brain, and behavior.

[6]  M. Goedert,et al.  Somatodendritic localization and hyperphosphorylation of tau protein in transgenic mice expressing the longest human brain tau isoform. , 1995, The EMBO journal.

[7]  Alexandra Flemming,et al.  Infectious disease: Unravelling SARS lethality , 2005, Nature Reviews Drug Discovery.

[8]  A. Delacourte,et al.  Similar brain tau pathology in DM2/PROMM and DM1/Steinert disease , 2005, Neurology.

[9]  L. Buée,et al.  Lithium treatment arrests the development of neurofibrillary tangles in mutant tau transgenic mice with advanced neurofibrillary pathology. , 2010, Journal of Alzheimer's disease : JAD.

[10]  T. Cooper,et al.  Overexpression of MBNL1 fetal isoforms and modified splicing of Tau in the DM1 brain: Two individual consequences of CUG trinucleotide repeats , 2008, Experimental Neurology.

[11]  P. Davies,et al.  Anesthesia-Induced Hyperphosphorylation Detaches 3-Repeat Tau from Microtubules without Affecting Their Stability In Vivo , 2008, The Journal of Neuroscience.

[12]  L. Buée,et al.  Loss of medial septum cholinergic neurons in THY-Tau22 mouse model: what links with tau pathology? , 2011, Current Alzheimer research.

[13]  G. Schellenberg,et al.  SUT-2 potentiates tau-induced neurotoxicity in Caenorhabditis elegans. , 2009, Human molecular genetics.

[14]  Y. Barde,et al.  Neurotrophins are required for nerve growth during development , 2001, Nature Neuroscience.

[15]  H. Hutter,et al.  A Caenorhabditis elegans model of tau hyperphosphorylation: Induction of developmental defects by transgenic overexpression of Alzheimer's disease-like modified tau , 2009, Neurobiology of Aging.

[16]  A. Delacourte,et al.  Specific tau variants in the brains of patients with myotonic dystrophy , 1996, Neurology.

[17]  R. Brandt,et al.  Interaction of tau with the neural plasma membrane mediated by tau's amino-terminal projection domain , 1995, The Journal of cell biology.

[18]  D. Campion,et al.  Cytoskeleton proteins are modulators of mutant tau-induced neurodegeneration in Drosophila. , 2007, Human molecular genetics.

[19]  G. Schellenberg,et al.  Tau isoform regulation is region‐ and cell‐specific in mouse brain , 2008, The Journal of comparative neurology.

[20]  A. Delacourte,et al.  Dysregulation of human brain microtubule-associated tau mRNA maturation in myotonic dystrophy type 1. , 2001, Human molecular genetics.

[21]  P. Davies,et al.  Characterization of Pathology in Transgenic Mice Over-Expressing Human Genomic and cDNA Tau Transgenes , 2000, Neurobiology of Disease.

[22]  D. Geschwind,et al.  Human Wild-Type Tau Interacts with wingless Pathway Components and Produces Neurofibrillary Pathology in Drosophila , 2002, Neuron.

[23]  A. Delacourte,et al.  Mice transgenic for the human myotonic dystrophy region with expanded CTG repeats display muscular and brain abnormalities. , 2001, Human molecular genetics.

[24]  J. Trojanowski,et al.  Neurodegenerative tauopathies. , 2001, Annual review of neuroscience.

[25]  L. Buée,et al.  Early Tau pathology involving the septo-hippocampal pathway in a Tau transgenic model: relevance to Alzheimer's disease. , 2009, Current Alzheimer research.

[26]  Andrew H Crosby,et al.  Disruption of cellular transport: a common cause of neurodegeneration? , 2003, The Lancet Neurology.

[27]  Joshua M. Shulman,et al.  Tauopathy in Drosophila: Neurodegeneration Without Neurofibrillary Tangles , 2001, Science.

[28]  W. Noble,et al.  Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[29]  H. Bujard,et al.  The Potential for β-Structure in the Repeat Domain of Tau Protein Determines Aggregation, Synaptic Decay, Neuronal Loss, and Coassembly with Endogenous Tau in Inducible Mouse Models of Tauopathy , 2008, The Journal of Neuroscience.

[30]  M. Vitek,et al.  Inhibition of neuronal maturation in primary hippocampal neurons from tau deficient mice. , 2001, Journal of cell science.

[31]  L. Buée,et al.  P1–062: Alzheimer's disease–like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits , 2006, The American journal of pathology.

[32]  L. Buée,et al.  Exploring the molecular function of PIN1 by nuclear magnetic resonance. , 2006, Current protein & peptide science.

[33]  E. Elliott,et al.  BAG-1 Associates with Hsc70·Tau Complex and Regulates the Proteasomal Degradation of Tau Protein* , 2007, Journal of Biological Chemistry.

[34]  A. Delacourte,et al.  Biochemistry of Tau in Alzheimer’s disease and related neurological disorders , 2008, Expert review of proteomics.

[35]  Charles Duyckaerts,et al.  Guadeloupean parkinsonism: a cluster of progressive supranuclear palsy-like tauopathy. , 2002, Brain : a journal of neurology.

[36]  R. Crowther,et al.  Assembly of microtubule-associated protein tau into Alzheimer-like filaments induced by sulphated glycosaminoglycans , 1996, Nature.

[37]  M. Goedert,et al.  Phosphorylation of microtubule‐associated protein tau by stress‐activated protein kinases in intact cells , 2002, FEBS letters.

[38]  S. Lovestone,et al.  GSK-3β inhibition reverses axonal transport defects and behavioural phenotypes in Drosophila , 2004, Molecular Psychiatry.

[39]  Patrick R. Hof,et al.  Tau protein isoforms, phosphorylation and role in neurodegenerative disorders 1 1 These authors contributed equally to this work. , 2000, Brain Research Reviews.

[40]  P. Hof,et al.  Neurofibrillary degeneration in amyotrophic lateral sclerosis/parkinsonism-dementia complex of Guam. Immunochemical characterization of tau proteins. , 1995, The American journal of pathology.

[41]  H. Geerts,et al.  Prominent axonopathy in the brain and spinal cord of transgenic mice overexpressing four-repeat human tau protein. , 1999, The American journal of pathology.

[42]  R. Nelson,et al.  Anesthesia Leads to Tau Hyperphosphorylation through Inhibition of Phosphatase Activity by Hypothermia , 2007, The Journal of Neuroscience.

[43]  S Lovestone,et al.  GSK-3β inhibition reverses axonal transport defects and behavioural phenotypes in Drosophila , 2004, Molecular Psychiatry.

[44]  D. Wilson,et al.  Free fatty acids stimulate the polymerization of tau and amyloid beta peptides. In vitro evidence for a common effector of pathogenesis in Alzheimer's disease. , 1997, The American journal of pathology.

[45]  M. Mercken,et al.  Glycogen Synthase Kinase-3β Phosphorylates Protein Tau and Rescues the Axonopathy in the Central Nervous System of Human Four-repeat Tau Transgenic Mice* , 2000, The Journal of Biological Chemistry.

[46]  S. Lovestone,et al.  Erratum: GSK-3β inhibition reverses axonal transport defects and behavioural phenotypes in Drosophila (Molecular Psychiatry (2004) 9 (522-530) DOI:10.1038/sj.mp.4001483) , 2004 .

[47]  J. Brion,et al.  Transgenic expression of the shortest human tau affects its compartmentalization and its phosphorylation as in the pretangle stage of Alzheimer's disease. , 1999, The American journal of pathology.

[48]  Gerard D Schellenberg,et al.  Molecular pathways that influence human tau-induced pathology in Caenorhabditis elegans. , 2006, Human molecular genetics.

[49]  A. Delacourte,et al.  Tau protein as a differential biomarker of tauopathies. , 2005, Biochimica et biophysica acta.